What question did this study set out to answer?

May 9, 2026

Baseline epidemiological differences between donanemab and lecanemab users in real-world settings: a retrospective cohort study

Key Points

This study aims to compare the baseline clinical and laboratory characteristics of patients treated with donanemab versus lecanemab.
Retrospective cohort study design was employed.
Epidemiological differences between patients using donanemab and lecanemab were analyzed.
Clinical and laboratory data were compared where p-values < 0.05 were considered significant.
Demographic variables between the two groups showed similarity.
Statistical analysis yielded a p-value of 0.0272, with a standardized mean difference (SMD) of 0.12.
Findings indicate real-world clinical selection patterns affecting treatment evaluations.

Abstract

AIMS: Donanemab and Lecanemab are anti-amyloid monoclonal antibodies recently approved for the treatment of Alzheimer's disease. Although their efficacy and safety have been investigated in randomized trials, real-world epidemiological data on treated populations remain limited. This study aimed to compare baseline clinical and laboratory characteristics of patients treated with donanemab versus lecanemab in routine practice. PATIENTS AND METHODS: < 0.05 were considered meaningfully different. RESULTS: = 0.0272; SMD = 0.12). CONCLUSION: While demographic variables were similar. These findings likely reflect real-world clinical selection patterns and should be accounted for in comparative effectiveness and safety analyses of anti-amyloid therapies.

Baseline epidemiological differences between donanemab and lecanemab users in real-world settings: a retrospective cohort study

Key Points

Abstract

Cite This Study

Also Consider

Also Consider